PURPOSE: Secretory clusterin (sCLU)/apolipoprotein J is an extracellular chaperone that has been functionally implicated in DNA repair, cell cycle regulation, apoptotic cell death, and tumorigenesis. It exerts a prosurvival function against most therapeutic treatments for cancer and is currently an antisense target in clinical trials for tumor therapy. However, the molecular mechanisms underlying its function remained largely unknown. EXPERIMENTAL DESIGN: The molecular effects of small interfering RNA-mediated sCLU depletion in nonstressed human cancer cells were examined by focusing entirely on the endogenously expressed sCLU protein molecules and combining molecular, biochemical, and microscopic approaches. RESULTS: We report here that sCLU depletion in nonstressed human cancer cells signals stress that induces p53-dependent growth retardation and high rates of endogenous apoptosis. We discovered that increased apoptosis in sCLU-depleted cells correlates to altered ratios of proapoptotic to antiapoptotic Bcl-2 protein family members, is amplified by p53, and is executed by mitochondrial dysfunction. sCLU depletion-related stress signals originate from several sites, because sCLU is an integral component of not only the secretory pathway but also the nucleocytosolic continuum and mitochondria. In the cytoplasm, sCLU depletion disrupts the Ku70-Bax complex and triggers Bax activation and relocation to mitochondria. We show that sCLU binds and thereby stabilizes the Ku70-Bax protein complex serving as a cytosol retention factor for Bax. CONCLUSIONS: We suggest that elevated sCLU levels may enhance tumorigenesis by interfering with Bax proapoptotic activities and contribute to one of the major characteristics of cancer cells, that is, resistance to apoptosis.
PURPOSE: Secretory clusterin (sCLU)/apolipoprotein J is an extracellular chaperone that has been functionally implicated in DNA repair, cell cycle regulation, apoptotic cell death, and tumorigenesis. It exerts a prosurvival function against most therapeutic treatments for cancer and is currently an antisense target in clinical trials for tumor therapy. However, the molecular mechanisms underlying its function remained largely unknown. EXPERIMENTAL DESIGN: The molecular effects of small interfering RNA-mediated sCLU depletion in nonstressed humancancer cells were examined by focusing entirely on the endogenously expressed sCLU protein molecules and combining molecular, biochemical, and microscopic approaches. RESULTS: We report here that sCLU depletion in nonstressed humancancer cells signals stress that induces p53-dependent growth retardation and high rates of endogenous apoptosis. We discovered that increased apoptosis in sCLU-depleted cells correlates to altered ratios of proapoptotic to antiapoptotic Bcl-2 protein family members, is amplified by p53, and is executed by mitochondrial dysfunction. sCLU depletion-related stress signals originate from several sites, because sCLU is an integral component of not only the secretory pathway but also the nucleocytosolic continuum and mitochondria. In the cytoplasm, sCLU depletion disrupts the Ku70-Bax complex and triggers Bax activation and relocation to mitochondria. We show that sCLU binds and thereby stabilizes the Ku70-Bax protein complex serving as a cytosol retention factor for Bax. CONCLUSIONS: We suggest that elevated sCLU levels may enhance tumorigenesis by interfering with Bax proapoptotic activities and contribute to one of the major characteristics of cancer cells, that is, resistance to apoptosis.
Authors: Konstantin S Leskov; Dmitry Y Klokov; Jing Li; Timothy J Kinsella; David A Boothman Journal: J Biol Chem Date: 2003-01-24 Impact factor: 5.157
Authors: Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave Journal: J Natl Cancer Inst Date: 2005-09-07 Impact factor: 13.506
Authors: I Viard; P Wehrli; L Jornot; R Bullani; J L Vechietti; J A Schifferli; J Tschopp; L E French Journal: J Invest Dermatol Date: 1999-03 Impact factor: 8.551
Authors: Konstantin S Leskov; Shinako Araki; John-Paul Lavik; Jose A Gomez; Vivian Gama; Efstathios S Gonos; Ioannis P Trougakos; Shigemi Matsuyama; David A Boothman Journal: J Biol Chem Date: 2011-09-27 Impact factor: 5.157
Authors: Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261
Authors: Shinwu Jeong; Dolena R Ledee; Gabriel M Gordon; Tatsuo Itakura; Nitin Patel; Aaron Martin; M Elizabeth Fini Journal: Am J Pathol Date: 2012-03-20 Impact factor: 4.307
Authors: Daniel Fleck; Lilian Phu; Erik Verschueren; Trent Hinkle; Mike Reichelt; Tushar Bhangale; Benjamin Haley; Yuanyuan Wang; Robert Graham; Donald S Kirkpatrick; Morgan Sheng; Baris Bingol Journal: J Neurosci Date: 2019-04-04 Impact factor: 6.167